MX2018011016A - Formulaciones estables para liofilizar particulas terapeuticas. - Google Patents

Formulaciones estables para liofilizar particulas terapeuticas.

Info

Publication number
MX2018011016A
MX2018011016A MX2018011016A MX2018011016A MX2018011016A MX 2018011016 A MX2018011016 A MX 2018011016A MX 2018011016 A MX2018011016 A MX 2018011016A MX 2018011016 A MX2018011016 A MX 2018011016A MX 2018011016 A MX2018011016 A MX 2018011016A
Authority
MX
Mexico
Prior art keywords
stable formulations
therapeutic particles
lyophilizing
lyophilizing therapeutic
nanoparticles
Prior art date
Application number
MX2018011016A
Other languages
English (en)
Inventor
Low Susan
Troiano Greg
Song Young-Ho
Joshi Ujjwal
TRAN Jeanne
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2018011016A publication Critical patent/MX2018011016A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción generalmente se relaciona con composiciones farmacéuticas liofilizadas que comprenden nanopartículas poliméricas que, después de la reconstitución, tienen bajos niveles de tamaño de partícula de más de 10 micras. Otros aspectos de la invención incluyen métodos para elaborar tales nanopartículas.
MX2018011016A 2016-03-25 2017-03-16 Formulaciones estables para liofilizar particulas terapeuticas. MX2018011016A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662313436P 2016-03-25 2016-03-25
US201762461410P 2017-02-21 2017-02-21
PCT/IB2017/051543 WO2017163155A1 (en) 2016-03-25 2017-03-16 Stable formulations for lyophilizing therapeutic particles

Publications (1)

Publication Number Publication Date
MX2018011016A true MX2018011016A (es) 2019-01-10

Family

ID=58398230

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018011016A MX2018011016A (es) 2016-03-25 2017-03-16 Formulaciones estables para liofilizar particulas terapeuticas.

Country Status (12)

Country Link
US (1) US20190099374A1 (es)
EP (1) EP3432866A1 (es)
JP (1) JP2019512516A (es)
KR (1) KR20180115750A (es)
CN (1) CN109152744A (es)
AU (1) AU2017236659A1 (es)
BR (1) BR112018068598A2 (es)
CA (1) CA2961760A1 (es)
IL (1) IL261459A (es)
MX (1) MX2018011016A (es)
RU (1) RU2018133578A (es)
WO (1) WO2017163155A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018372924A1 (en) * 2017-11-22 2020-04-23 Hillstream Biopharma Inc. Polymeric nanoparticles comprising bortezomib
CN117224699B (zh) * 2023-09-05 2024-03-19 贵州大学 一种纳米复合物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060286171A1 (en) * 2005-06-17 2006-12-21 Tianhong Zhou Bone morphogenetic protein formulations
CN103932972A (zh) * 2009-03-30 2014-07-23 天蓝制药公司 聚合物-药剂缀合物、颗粒、组合物和相关使用方法
JP5891175B2 (ja) * 2009-12-11 2016-03-22 バインド セラピューティックス インコーポレイテッド 治療用粒子の凍結乾燥に対する安定製剤
CN102198106B (zh) * 2011-05-31 2012-08-29 武汉普生制药有限公司 注射用兰索拉唑纳米粒冻干制剂及其制备方法
UA121967C2 (uk) * 2014-03-14 2020-08-25 Пфайзер Інк. Терапевтичні наночастинки, які містять терапевтичний засіб, та способи їх отримання та застосування
BR112017000022A2 (pt) * 2014-07-03 2017-11-07 Pfizer nanoparticulas terapêuticas direcionadas a alvo e métodos de produção e uso dessas partículas

Also Published As

Publication number Publication date
AU2017236659A1 (en) 2018-09-13
US20190099374A1 (en) 2019-04-04
KR20180115750A (ko) 2018-10-23
CA2961760A1 (en) 2017-09-25
JP2019512516A (ja) 2019-05-16
IL261459A (en) 2018-10-31
WO2017163155A1 (en) 2017-09-28
EP3432866A1 (en) 2019-01-30
CN109152744A (zh) 2019-01-04
RU2018133578A3 (es) 2020-04-27
RU2018133578A (ru) 2020-04-27
BR112018068598A2 (pt) 2019-02-19

Similar Documents

Publication Publication Date Title
MX2022005290A (es) Compuestos heterociclicos como inmunomoduladores.
WO2011072218A3 (en) Stable formulations for lyophilizing therapeutic particles
PH12018501084A1 (en) Heterocyclic compounds as immunomodulators
MX2022000789A (es) Compuestos heterociclicos como inmunomoduladores.
MX2020001525A (es) Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
SG10201908839QA (en) 2,4-dihydroxy-nicotinamides as apj agonists
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
EA202190331A1 (ru) Композиции терапевтически активных частиц с модифицированной поверхностью, полученные путем ультрабыстрой заморозки
PH12016501519A1 (en) Solid pharmaceutical compositions comprising biopterin derivatives and uses of such compositions
MX2018012618A (es) Composiciones farmaceuticas orales de mesalazina.
MX2020001885A (es) Formulaciones de daptomicina.
PH12017500451A1 (en) Crystalline forms of 6-((6,7-dimethoxyquinazolin-4-yl) oxy)-n, 2-dimethylbenzofuran -3- carboxamide
MX2019005102A (es) Poxvirus quimericos sinteticos.
MX2019005775A (es) Formulacion farmaceutica parenteral que contiene acido carglumico.
MX2019004580A (es) Formulaciones farmaceuticas y metodos para prepararlas.
IN2014CH00840A (es)
MX2018011016A (es) Formulaciones estables para liofilizar particulas terapeuticas.
WO2017075171A3 (en) Pamam dendrimer based cest imaging agents and uses thereof
SG10201805890QA (en) Compositions and methods for treatment of abnormal cell growth
IN2013MU01177A (es)
ZA202002129B (en) Oral bendamustine formulations
MX2017013879A (es) Composiciones que comprenden anakinra.
SG10201902499VA (en) Therapeutic nanoparticles and related compositions, methods and systems
WO2015159155A3 (en) Novel ademetionine formulations